BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Perazzo H, Cardoso SW, Yanavich C, Nunes EP, Morata M, Gorni N, da Silva PS, Cardoso C, Almeida C, Luz P, Veloso VG, Grinsztejn B. Predictive factors associated with liver fibrosis and steatosis by transient elastography in patients with HIV mono-infection under long-term combined antiretroviral therapy. J Int AIDS Soc. 2018;21:e25201. [PMID: 30394678 DOI: 10.1002/jia2.25201] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 8.3] [Reference Citation Analysis]
Number Citing Articles
1 Rose PC, De la Rey Nel E, Cotton MF, Otwombe K, Browne SH, Frigati LJ, Rabie H, Innes S. Decreased Hepatic Steatosis in South African Adolescents With Perinatal HIV Switching to Dolutegravir-containing Regimens. Pediatr Infect Dis J 2023. [PMID: 36917035 DOI: 10.1097/INF.0000000000003904] [Reference Citation Analysis]
2 Duarte M, Tien P, Ma Y, Noworolski SM, Korn N, Price JC. Controlled attenuation parameter accurately detects liver steatosis in people with HIV. AIDS 2022;36:2147-52. [PMID: 35950941 DOI: 10.1097/QAD.0000000000003351] [Reference Citation Analysis]
3 Villa G, Owusu D, Smith C, Azumah M, Abdullahi A, Phillips S, Sayeed L, Austin H, Chadwick D, Phillips RO, Geretti AM. Liver steatosis and fibrosis in people with human immunodeficiency virus in West Africa and the relationship with hepatitis B virus coinfection. Hepatol Commun 2022;6:3036-51. [PMID: 36103301 DOI: 10.1002/hep4.2000] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Li B, Zhang L, Liu Y, Xiao J, Li C, Fan L, Duan Y, Xiao J, Hao Y, Han J, Kong Y, Zhao H. A novel prediction model to evaluate the probability of CD4+/CD8+ cell ratio restoration in HIV-infected individuals. AIDS 2022;36:795-804. [PMID: 35013083 DOI: 10.1097/QAD.0000000000003167] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Sebastiani G, Milic J, Cervo A, Saeed S, Krahn T, Kablawi D, Al Hinai AS, Lebouché B, Wong P, Deschenes M, Gioè C, Cascio A, Mazzola G, Guaraldi G. Two-Tier Care Pathways for Liver Fibrosis Associated to Non-Alcoholic Fatty Liver Disease in HIV Mono-Infected Patients. JPM 2022;12:282. [DOI: 10.3390/jpm12020282] [Reference Citation Analysis]
6 Rose PC, Nel ED, Cotton MF, Pitcher RD, Otwombe K, Browne SH, Innes S. Prevalence and Risk Factors for Hepatic Steatosis in Children With Perinatal HIV on Early Antiretroviral Therapy Compared to HIV-Exposed Uninfected and HIV-Unexposed Children. Front Pediatr 2022;10:893579. [PMID: 35757117 DOI: 10.3389/fped.2022.893579] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Yanavich C, Perazzo H, Li F, Tobin N, Lee D, Zabih S, Morata M, Almeida C, Veloso VG, Grinsztejn B, Aldrovandi GM. A pilot study of microbial signatures of liver disease in those with HIV mono-infection in Rio de Janeiro, Brazil. AIDS 2022;36:49-58. [PMID: 34873092 DOI: 10.1097/QAD.0000000000003084] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Rossetti B, Borgo V, Emiliozzi A, Colaneri M, Zanelli G, d’Alessandro M, Motta D, Maiocchi L, Montagnani F, Moioli MC, Baiguera C, Sambo M, Pieri TC, Valsecchi P, Bruno R, Puoti M, Fabbiani M. Discordant Liver Fibrosis Predictors in Virologically Suppressed People Living with HIV without Hepatitis Virus Infection. Diagnostics 2021;12:14. [DOI: 10.3390/diagnostics12010014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Kamkwalala AR, Garg A, Roy U, Matthews A, Castillo-Mancilla J, Lake JE, Sebastiani G, Yin M, Brown TT, Kamer AR, Jabs DA, Ellis RJ, Boffito M, Greene M, Schmalzle S, Siegler E, Erlandson KM, Moore DJ. Current Considerations for Clinical Management and Care of People with HIV: Findings from the 11th Annual International HIV and Aging Workshop. AIDS Res Hum Retroviruses 2021;37:807-20. [PMID: 34405689 DOI: 10.1089/AID.2021.0059] [Reference Citation Analysis]
10 Bischoff J, Gu W, Schwarze-Zander C, Boesecke C, Wasmuth JC, van Bremen K, Dold L, Rockstroh JK, Trebicka J. Stratifying the risk of NAFLD in patients with HIV under combination antiretroviral therapy (cART). EClinicalMedicine 2021;40:101116. [PMID: 34522873 DOI: 10.1016/j.eclinm.2021.101116] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 8.5] [Reference Citation Analysis]
11 de Almeida CF, da Silva PS, Cardoso CSA, Moreira NG, Antunes JC, de Andrade MM, Silva J, Araujo MC, Peres WAF, do Brasil PEAA, Moreira RI, Cardoso SW, Veloso VG, Grinsztejn B, de Brito PD, Perazzo H. Relationship between Dietary Fatty Acid Intake with Nonalcoholic Fatty Liver Disease and Liver Fibrosis in People with HIV. Nutrients 2021;13:3462. [PMID: 34684463 DOI: 10.3390/nu13103462] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Fourman LT, Stanley TL, Zheng I, Pan CS, Feldpausch MN, Purdy J, Aepfelbacher J, Buckless C, Tsao A, Corey KE, Chung RT, Torriani M, Kleiner DE, Hadigan CM, Grinspoon SK. Clinical Predictors of Liver Fibrosis Presence and Progression in Human Immunodeficiency Virus-Associated Nonalcoholic Fatty Liver Disease. Clin Infect Dis 2021;72:2087-94. [PMID: 32270862 DOI: 10.1093/cid/ciaa382] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
13 Ajmera VH, Cachay ER, Ramers CB, Bassirian S, Singh S, Bettencourt R, Richards L, Hamilton G, Middleton M, Fowler K, Sirlin C, Loomba R. Optimal Threshold of Controlled Attenuation Parameter for Detection of HIV-Associated NAFLD With Magnetic Resonance Imaging as the Reference Standard. Clin Infect Dis 2021;72:2124-31. [PMID: 32975278 DOI: 10.1093/cid/ciaa429] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
14 Bakasis AD, Androutsakos T. Liver Fibrosis during Antiretroviral Treatment in HIV-Infected Individuals. Truth or Tale? Cells 2021;10:1212. [PMID: 34063534 DOI: 10.3390/cells10051212] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
15 Merchante N, Saroli Palumbo C, Mazzola G, Pineda JA, Téllez F, Rivero-Juárez A, Ríos-Villegas MJ, Maurice JB, Westbrook RH, Judge R, Guaraldi G, Schepis F, Perazzo H, Rockstroh J, Boesecke C, Klein MB, Cervo A, Ghali P, Wong P, Petta S, De Ledinghen V, Macías J, Sebastiani G. Prediction of Esophageal Varices by Liver Stiffness and Platelets in Persons With Human Immunodeficiency Virus Infection and Compensated Advanced Chronic Liver Disease. Clin Infect Dis 2020;71:2810-7. [PMID: 31813962 DOI: 10.1093/cid/ciz1181] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
16 Al-Nimer MS. Is COVID-19-induced liver injury different from other RNA viruses?‎ World J Meta-Anal 2021; 9(2): 108-127 [DOI: 10.13105/wjma.v9.i2.108] [Reference Citation Analysis]
17 van Santen DK, Agius PA, Sasadeusz J, Fairley CK, Sievert W, Gane E, Iser D, O'Reilly M, Medland NA, Moore R, Hellard ME, Hoy JF, Doyle JS; Co-EC Study Group. The Impact of Markers of HIV Infection on Change in Liver Stiffness in People With HIV and Hepatitis C Virus Co-infection After Treatment and Cure of Hepatitis C. J Acquir Immune Defic Syndr 2020;85:e81-9. [PMID: 32842055 DOI: 10.1097/QAI.0000000000002487] [Reference Citation Analysis]
18 Kirkegaard-Klitbo DM, Fuchs A, Stender S, Sigvardsen PE, Kühl JT, Kofoed KF, Køber L, Nordestgaard BG, Bendtsen F, Mocroft A, Lundgren J, Nielsen SD, Benfield T. Prevalence and Risk Factors of Moderate-to-Severe Hepatic Steatosis in Human Immunodeficiency Virus Infection: The Copenhagen Co-morbidity Liver Study. J Infect Dis 2020;222:1353-62. [PMID: 32417886 DOI: 10.1093/infdis/jiaa246] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
19 Krahn T, Martel M, Sapir-Pichhadze R, Kronfli N, Falutz J, Guaraldi G, Lebouche B, Klein MB, Wong P, Deschenes M, Ghali P, Sebastiani G. Nonalcoholic Fatty Liver Disease and the Development of Metabolic Comorbid Conditions in Patients With Human Immunodeficiency Virus Infection. J Infect Dis 2020;222:787-97. [PMID: 32249283 DOI: 10.1093/infdis/jiaa170] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
20 Cervo A, Shengir M, Patel K, Sebastiani G. NASH in HIV. Curr HIV/AIDS Rep 2020;17:601-14. [PMID: 32984925 DOI: 10.1007/s11904-020-00531-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
21 Yanavich C, Pacheco AG, Cardoso SW, Nunes EP, Chaves U, Freitas G, Santos R, Morata M, Veloso VG, Grinsztejn B, Perazzo H. Diagnostic value of serological biomarkers for detection of non-alcoholic fatty liver disease (NAFLD) and/or advanced liver fibrosis in people living with HIV. HIV Med 2021;22:445-56. [PMID: 33529485 DOI: 10.1111/hiv.13060] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
22 Jongraksak T, Sobhonslidsuk A, Jatchavala J, Warodomwichit D, Kaewduang P, Sungkanuparph S. Prevalence and predicting factors of metabolic-associated fatty liver disease diagnosed by transient elastography with controlled attenuation parameters in HIV-positive people. Int J STD AIDS 2021;32:266-75. [DOI: 10.1177/0956462420960997] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
23 Rasoulinejad M, Seyed Alinaghi SA, Sohrabi MR, Badie BM, Manshadi SAD, Nezhad MH, Khatami SR. Prevalence and Factors Associated with Hepatic Steatosis and Fibrosis Using Fibroscan in HIV-positive Patients Treated with Anti-retroviral (ARV) Medicines Referred to the Biggest Hospital in Tehran, 2018 to 2019. TOAIDJ 2020;14:108-13. [DOI: 10.2174/1874613602014010108] [Reference Citation Analysis]
24 Kirkegaard-Klitbo DM, Bendtsen F, Lundgren J, de Knegt RJ, Kofoed KF, Nielsen SD, Benfield T. Increased Prevalence of Liver Fibrosis in People Living With Human Immunodeficiency Virus Without Viral Hepatitis Compared to Population Controls. J Infect Dis 2021;224:443-52. [PMID: 33320268 DOI: 10.1093/infdis/jiaa763] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
25 Bailin SS, Gabriel CL, Wanjalla CN, Koethe JR. Obesity and Weight Gain in Persons with HIV. Curr HIV/AIDS Rep 2020;17:138-50. [PMID: 32072466 DOI: 10.1007/s11904-020-00483-5] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 10.7] [Reference Citation Analysis]
26 Maurice JB, Goldin R, Hall A, Price JC, Sebastiani G, Morse CG, Prat L, Perazzo H, Garvey L, Ingiliz P, Guaraldi G, Tsochatzis E, Lemoine M. Increased BMI and Type 2 diabetes are the main predictors of NAFLD and advanced fibrosis in liver biopsies of patients with HIV mono-infection. Clin Infect Dis 2020:ciaa1302. [PMID: 32877569 DOI: 10.1093/cid/ciaa1302] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
27 Guaraldi G, Maurice JB, Marzolini C, Monteith K, Milic J, Tsochatzis E, Bhagani S, Morse CG, Price JC, Ingiliz P, Lemoine M, Sebastiani G; SHIVER Network. New Drugs for NASH and HIV Infection: Great Expectations for a Great Need. Hepatology 2020;71:1831-44. [PMID: 32052857 DOI: 10.1002/hep.31177] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
28 Aepfelbacher JA, Balmaceda J, Purdy J, Mattingly A, Zambell K, Hawkins K, Chairez C, Curl KA, Dee N, Hadigan C. Increased Prevalence of Hepatic Steatosis in Young Adults With Lifelong HIV. J Infect Dis. 2019;220:266-269. [PMID: 30852587 DOI: 10.1093/infdis/jiz096] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
29 Kaplan A, Price JC. HIV-Associated NAFLD: Disease Burden and Management. Curr Hepatology Rep 2019;18:482-91. [DOI: 10.1007/s11901-019-00501-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
30 Morrison M, Hughes HY, Naggie S, Syn WK. Nonalcoholic Fatty Liver Disease Among Individuals with HIV Mono-infection: A Growing Concern? Dig Dis Sci 2019;64:3394-401. [PMID: 31643035 DOI: 10.1007/s10620-019-05861-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
31 Sebastiani G, Cocciolillo S, Mazzola G, Malagoli A, Falutz J, Cervo A, Petta S, Pembroke T, Ghali P, Besutti G, Franconi I, Milic J, Cascio A, Guaraldi G. Application of guidelines for the management of nonalcoholic fatty liver disease in three prospective cohorts of HIV-monoinfected patients. HIV Med 2020;21:96-108. [PMID: 31642599 DOI: 10.1111/hiv.12799] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
32 Praktiknjo M, Djayadi N, Mohr R, Schierwagen R, Bischoff J, Dold L, Pohlmann A, Schwarze-Zander C, Wasmuth JC, Boesecke C, Rockstroh JK, Trebicka J. Fibroblast growth factor 21 is independently associated with severe hepatic steatosis in non-obese HIV-infected patients. Liver Int 2019;39:1514-20. [PMID: 30916873 DOI: 10.1111/liv.14107] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
33 Calza L, Colangeli V, Borderi M, Coladonato S, Tazza B, Fornaro G, Badia L, Guardigni V, Verucchi G, Viale P. Improvement in liver steatosis after the switch from a ritonavir-boosted protease inhibitor to raltegravir in HIV-infected patients with non-alcoholic fatty liver disease. Infect Dis (Lond) 2019;51:593-601. [PMID: 31219362 DOI: 10.1080/23744235.2019.1629008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
34 Zicari S, Sessa L, Cotugno N, Ruggiero A, Morrocchi E, Concato C, Rocca S, Zangari P, Manno EC, Palma P. Immune Activation, Inflammation, and Non-AIDS Co-Morbidities in HIV-Infected Patients under Long-Term ART. Viruses 2019;11:E200. [PMID: 30818749 DOI: 10.3390/v11030200] [Cited by in Crossref: 152] [Cited by in F6Publishing: 161] [Article Influence: 38.0] [Reference Citation Analysis]